Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr;269(4):1786-1801.
doi: 10.1007/s00415-021-10783-4. Epub 2021 Sep 5.

Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders

Collaborators, Affiliations
Review

Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders

Hesham Abboud et al. J Neurol. 2022 Apr.

Abstract

Neuromyelitis optica spectrum disorders (NMOSD) are a group of autoimmune inflammatory conditions that primarily target the optic nerves, spinal cord, brainstem, and occasionally the cerebrum. NMOSD is characterized by recurrent attacks of visual, motor, and/or sensory dysfunction that often result in severe neurological deficits. In recent years, there has been a significant progress in relapse treatment and prevention but the residual disability per attack remains high. Although symptomatic and restorative research has been limited in NMOSD, some therapeutic approaches can be inferred from published case series and evidence from multiple sclerosis literature. In this review, we will discuss established and emerging therapeutic options for symptomatic treatment and restoration of function in NMOSD. We highlight NMOSD-specific considerations and identify potential areas for future research. The review covers pharmacologic, non-pharmacologic, and neuromodulatory approaches to neuropathic pain, tonic spasms, muscle tone abnormalities, sphincter dysfunction, motor and visual impairment, fatigue, sleep disorders, and neuropsychological symptoms. In addition, we briefly discuss remyelinating agents and mesenchymal stem cell transplantation in NMOSD.

Keywords: Mesenchymal stem cells; NMO; NMOSD; Neuromyelitis optica; Neuropathic pain; Remyelination; Symptomatic; Tonic spasms.

PubMed Disclaimer

Conflict of interest statement

H. Abboud is a consultant and speaker for Biogen, Genentech-Roche, Bristol Myers Squibb, Alexion, and Horizon. He receives research support from Genentech-Roche, Novartis, Sanofi-Genzyme, and Bristol Myers Squibb to conduct clinical trials. M. Mealy is an employee of Horizon Therapeutics plc, Deerfield IL, (formerly Viela Bio) but her contribution to the manuscript herein does not necessarily represent the views of Horizon. A. Goodman received personal compensation for consulting from Teva and Adamas; received research support from Biogen, Genentech-Roche, Sanofi-Genzyme, and Teva. A Salazar-Camelo, N. George, SM Planchon, and M. Matiello have nothing to disclose.

References

    1. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614–625. doi: 10.1056/NEJMoa1900866. - DOI - PubMed
    1. Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352–1363. doi: 10.1016/S0140-6736(19)31817-3. - DOI - PubMed
    1. Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(22):2114–2124. doi: 10.1056/NEJMoa1901747. - DOI - PubMed
    1. Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord. 2012;1(4):180–187. doi: 10.1016/j.msard.2012.06.002. - DOI - PMC - PubMed
    1. Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: evaluation of 871 attacks and 1153 treatment courses. Ann Neurol. 2016;79(2):206–216. doi: 10.1002/ana.24554. - DOI - PubMed